> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Discuss Sarepta NDA for Duchenne Muscular Dystrophy
- URL: https://www.fdaweb.com/panel-to-discuss-sarepta-nda-for-duchenne-muscular-dystrophy/
- Published: 2016-03-14T12:00:00.000Z
- Updated: 2026-09-15T02:43:35.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135074

*Federal Register* Notice: FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet 4/25, from 8 a.m. to 5:30 p.m. at the Park Marriott Hotel and Conference Center, Chesapeake Ballroom, 3501 University Blvd. East, Hyattsville, MD. This meeting is a reschedule of a postponed meeting announced in the 12/18/15 Federal Register originally scheduled for 1/22\. The committee will discuss a Sarepta Therapeutics NDA for eteplirsen injection for intravenous infusion for treating Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Contact **Moon Hee V. Choi**, (301) 796-9001\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-03-14/pdf/2016-05683.pdf?ref=fdaweb.com)